<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Forty of the 550 patients (7%) entered to the 11q23 Workshop had secondary (s) <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (nine cases), s-<z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (25 cases, predominantly of FAB type M5), s-<z:hpo ids='HP_0002488'>acute leukemia</z:hpo> unspecified (one case) or s-<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (five cases) following treatment for a primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0003002'>Breast cancer</z:hpo> (12 cases) and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (eight cases) were the most frequent primaries </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-three patients had been treated with either an epipodophyllotoxin (seven patients) or an <z:chebi fb="0" ids="48120">anthracycline</z:chebi> (10 cases) or both (four cases) frequently combined with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> (12 cases) and with radiotherapy (six cases) </plain></SENT>
<SENT sid="3" pm="."><plain>Two further patients had <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> and two had radiotherapy alone </plain></SENT>
<SENT sid="4" pm="."><plain>Time between diagnosis of the primary and <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary malignancy</z:e> was between 10 months and 22 years (median 24 months) </plain></SENT>
<SENT sid="5" pm="."><plain>The incidence of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">secondary malignancies</z:e> in 11q23 subgroups was: t(11;19)(q23;p13.1) (33%), t(9;11) (8%), t(4;11) (5.5%), t(10;11)(5%), t (6;11) (3%), del11q23(2%) and 10 patients had a rare 'other' abnormality </plain></SENT>
<SENT sid="6" pm="."><plain>No associations were seen between type of prior <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> and 11q23 subgroup, or between prior <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> and <z:hpo ids='HP_0001909'>leukemia</z:hpo> subtype </plain></SENT>
<SENT sid="7" pm="."><plain>Remission, when achieved (32 patients), was short (median 5 months) </plain></SENT>
<SENT sid="8" pm="."><plain>Two patients survived following a bone marrow transplant for s-<z:hpo ids='HP_0001909'>leukemia</z:hpo> and s-<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
</text></document>